MULTI-PHASE RELEASE POTASSIUM GUAIACOLSULFONATE COMPOSITIONS

• US 20100041759A1
• Filed: 10/21/2009
• Published: 02/18/2010
• Est. Priority Date: 10/04/2006
• Status: Abandoned Application

• Current Assignee: Glynn Wilson, Matthew F. Heil
• Original Assignee: Glynn Wilson, Matthew F. Heil
• Inventors: Heil, Matthew F., Wilson, Glynn
• Application Number:
  US12/582,872
• Publication Number:
  US 20100041759A1
• Time in Patent Office: Days
• US Class Current: 514/576
• CPC Class Codes: A61K 31/075 Ethers or acetals
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in a gradient, decreasing the side effects associated with rapidly elevated blood levels. In another embodiment, the drug is bound to an ion-exchange resin, which can be suspended in a liquid or incorporated into a matrix for delayed, sustained and/or pulsed release. Dosage unit forms may be tablets, gels, liquids, capsules, beads, microparticles, films or lozenges. Multi-phase delivery can also be achieved through the use of a kit that provides for dosage escalation. The formulations are useful in the treatment of one or more symptoms of coughs, colds, sinusitis and other respiratory illnesses. The formulations are also useful in the treatment or relief of fibromyalgia, pain, and Irritable Bowel Syndrome.

Claims

1. A multi-phase guaiacolsulfonate salt formulation.

2. The formulation of claim 1, wherein the salt is potassium.

3. The formulation of claim 1 further comprising one or more additional active agents.

4. The formulation of claim 3, wherein the additional active agent is selected from the group consisting of expectorants, antitussives, decongestants, antihistamines, and analgesics.

5. The formulation of claim 4, wherein the additional active agent is selected from the group consisting of dextromethorphan hydrobromide, codeine, hydrocodone, phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine, chlorpheniramine maleate, brompheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, phenyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, clemastine fumerate, aspirin, ibuprofen, acetaminophen, naprosin, potassium, guaiacolsulfonate and combinations thereof.

6. The formulation of claim 5, wherein the additional active agent is guaifenesin, bromohexidine, theobromine or combinations thereof.

7. The formulation of claim 1 comprising an immediate release guaiacolsulfonate component.

8. The formulation of claim 1 comprising a delayed release guaiacolsulfonate component.

9. The formulation of claim 1 comprising a sustained release guaiacolsulfonate component.

10. The formulation of claim 1 comprising a pulsed release guaiacolsulfonate component.

11. The formulation of claim 1 comprising an immediate release and a delayed, sustained or pulsed guaiacolsulfonate component.

12. The formulation of claim 11 comprising a bilayer tablet containing an immediate release component of potassium guaiacolsulfonate in one layer and a sustained release and/or delayed release component of potassium guaiacolsulfonate in the second layer.

13. The formulation of claim 1, wherein the formulation is designed to release guaiacolsulfonate over a 1-24 hr period.

14. The formulation of claim 1, wherein a total quantity of guaiacolsulfonate is from about 600 mg to about 3600 mg,

15. The formulation of claim 1, wherein a total quantity of guaiacolsulfonate is from about 100 mg/day to about 2,400 mg/day.

16. The formulation of claim 11 for immediate release of about 100 to 600 mg guaiacolsulfonate and sustained release of about 600 to 1200 mg guaiacolsulfonate.

17. The formulation of claim 10 comprising pulsed release of three doses of 100 to 400 mg in a multiparticulate system with delayed release beads.

18. The formulation of claim 3, wherein a ratio of a total quantity of potassium guaiacolsulfonate to the additional active agent is from about 1:

1 to about 100;

1 by weight.

19. The formulation of claim 3, wherein the release of one or more additional active agents may be immediate, sustained, delayed release or combinations thereof.

20. The formulation of claim 1 in a package of individual unit dosage forms providing different dosages of guaiacolsulfonate.

21. The formulation of claim 1 in a package of individual unit dosage forms marked with instructions providing an administration regime for different dosages of guaiacolsulfonate.

22. The formulation of claim 1 in a package of individual unit dosage forms providing multiple formulations that contain different guaiacolsulfonate doses or different drug combinations, one of which includes guaiacolsulfonate, that can be taken at different times on different days or different times of the day.

23. The formulation of claim 22 wherein the regime provides for an escalating dosage.

24. The formulation of claim 1, wherein the dosage unit form is selected from the group consisting of tablets, gels, liquids, capsules, beads, microparticles, films, lozenges, and sublingual tablets.

25. The formulation of claim 24 comprising a mixture of immediate, delayed or sustained release granules compressed into a solid matrix tablet, a rapidly disintegrating tablet, or filled into a capsule.

26. The formulation of claim 1, wherein the solid matrix tablet contains silicified microcrystalline cellulose

27. The formulation of claim 1, wherein the dosage form is a system, designed to achieve absorption of guaiacolsulfonate through the buccal cavity.

28. The formulation of claim 27, wherein, the dosage form further comprises an absorption enhancer designed to increase the bioavailability of guaiacolsulfonate across the mucosa.

29. A method of administering guaiacolsulfonate comprising administering the formulation of claim 1.

30. The method of claim 29, wherein the guaiacolsulfonate is administered to an individual for relief of one or more symptoms associated with a disorder selected from the group consisting of sleep disorders, hypothyroidism, lyme disease, chronic myofascial pain, fibromyalgia, and hormonal imbalances.

31. The method of claim 29, wherein the guaiacolsulfonate is administered to an individual with pain, including back pain, pelvic pain, and Ehlers-Danlos Syndrome.

32. The method of claim 29, wherein the guaiacolsulfonate is administered to an individual with restless leg syndrome.

33. The method of claim 29, wherein the guaiacolsulfonate is administered to an individual to induce muscle relaxation in a dosage equivalent to between about 600 mg/day and about 3,600 mg/day.

34. The method of claim 29, wherein the guaiacolsulfonate is administered to an individual with Irritable Bowel Syndrome.

35. The method of claim 29, wherein the guaiacolsulfonate is administered to an individual to potentiate the effects of pain analgesics, where the analgesic is selected from the group consisting of paracetamol, morphine, opiates, doxepin, naprosin, aspirin, ibuprofen, acetaminophen.

36. The method of claim 29, wherein the guaiacolsulfonate is administered to treat coughing and symptoms or diseases associated with coughing.

37. The method of claim 29, wherein the guaiacolsulfonate is packaged in a unified medication package comprising a multiplicity of medications, functional indicia, and instructions for coordinating the medications together as a regimen.

38. The method of claim 29 comprising providing medication dosages in blister packs or pouches, organized into event modules associated with particular daily events, and having corresponding event indicia.

39. The method of claim 38, wherein the event modules are further organized into day modules having day indicia.

40. The method of claim 38, wherein the event modules are organized into compartments of a box.